Search Results

Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells

Authors: Baron, Antonella; Mancini, Mariangela; Caldwell, Elizabeth; Cabrelle, Anna; Bernardi, Paolo; Pagano, Francesco

Source: BJU International, Volume 103, Number 9, May 2009 , pp. 1275-1283(9)

Publisher: Blackwell Publishing

Multi centre study to evaluate the safety and efficacy of phytotherapeuticum permixon in the treatment of chronic prostatitis/chronic pelvic pain syndrome

Authors: Reissigl A.; Pointner J.; Djavan B.; Remzi M.; Brunner J.; Obwexer S.; Marberger M.

Source: European Urology Supplements, Volume 2, Number 1, February 2003 , pp. 15-15(1)

Publisher: Elsevier

Why does the lipido-sterolic extract of serenoa repens permixon(R) fail to inhibit prostate specific antigen whilst maintaining its 5 alpha reductase inhibitory activity in the human prostate

Authors: Habib F.; Ross M.

Source: European Urology Supplements, Volume 2, Number 1, February 2003 , pp. 20-20(1)

Publisher: Elsevier

Inhibition of type 1 and type 2 5-reductase activity by free fatty acids, active ingredients of Permixon⁽R)

Authors: Raynaud J.-P.; Cousse H.; Martin P.-M.

Source: The Journal of Steroid Biochemistry and Molecular Biology, Volume 82, Number 2, October 2002 , pp. 233-239(7)

Publisher: Elsevier

Effects of the lipido sterolic extract of serenoa repens (Permixon(R)) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients

Authors: Vela-Navarrete R.; Garcia-Cardoso J.; Barat A.; Manzarbeitia F.; Monton M.; Lopez-Farre A.

Source: European Urology Supplements, Volume 1, Number 1, January 2002 , pp. 62-62(1)

Publisher: Elsevier

The inhibition of nephrocalcinosis in an animal model with the lipido-sterolic extract of serenoa repens, Permixon(R)

Authors: Buck C.; More I.; Mahendra V.

Source: European Urology Supplements, Volume 1, Number 1, January 2002 , pp. 82-82(1)

Publisher: Elsevier

Comparison of a phytotherapeutic agent (permixon) with an alphablocker. (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study

Author: Debruyne F.

Source: European Urology Supplements, Volume 1, Number 1, January 2002 , pp. 108-108(1)

Publisher: Elsevier

Comparison of a Phytotherapeutic Agent (Permixon) with an -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

Authors: Debruyne F.; Koch G.; Boyle P.; Da Silva F.C.; Gillenwater J.G.; Hamdy F.C.; Perrin P.; Teillac P.; Vela-Navarrete R.; Raynaud J.-P.; For the members of the PERMAL Study Group

Source: European Urology, Volume 41, Number 5, May 2002 , pp. 497-507(11)

Publisher: Elsevier

Computerised Assessment of Maximum Urinary Flow: an Efficient, Consistent and Valid Approach

Authors: Witjes W.P.J.; de la Rosette J.J.M.C.H.; van den Berg-Segers A.; Colongo D.; Koch G.; Zlotta A.R.; Colau A.; de Wildt M.J.A.M.; Wijkstra H.

Source: European Urology, Volume 41, Number 2, February 2002 , pp. 206-213(8)

Publisher: Elsevier

Reproducibility and Clinical and Concurrent Validity of the MSF-4: A Four-Item Male Sexual Function Questionnaire for Patients with Benign Prostatic Hyperplasia

Authors: Marquis P.; Marrel A.

Source: Value in Health, Volume 4, Number 4, July 2001 , pp. 335-343(9)

Publisher: Blackwell Publishing

The Serenoa repens extract `Permixon' improves symptoms in benign prostatic hyperplasia

Source: Inpharma, Volume 1, Number 1238, 2000 , pp. 15-15(1)

Publisher: Adis International

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

Authors: Boyle P.; Robertson C.; Lowe F.; Roehrborn C.

Source: Urology, Volume 55, Number 4, April 2000 , pp. 533-539(7)

Publisher: Elsevier

Inhibition of Human Sperm Motility by Specific Herbs Used in Alternative Medicine

Authors: Ondrizek R.R.; Chan P.J.; Patton W.C.; King A.

Source: Journal of Assisted Reproduction and Genetics, Volume 16, Number 2, February 1999 , pp. 87-91(5)

Publisher: Springer

Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia

Authors: Wilde M.I.; Goa K.L.

Source: Drugs, Volume 57, Number 4, April 1999 , pp. 557-581(25)

Publisher: Adis International

This work was supported by a grant from Nutraceutical Corp., Ogden, Utah.Saw Palmetto (Serenoa repens) in Men with Lower Urinary Tract Symptoms: Effects on Urodynamic Parameters and Voiding Symptoms - the effects of Permixon on DHT formation (abstrac

Authors: Gerber G.S.; Zagaja G.P.; Bales G.T.; Chodak G.W.; Contreras B.A.

Source: Urology, Volume 51, Number 6, June 1998 , pp. 1003-1007(5)

Publisher: Elsevier

EFFECT OF SERENOA REPENS EXTRACT (PERMIXON ) ON ESTRADIOL/TESTOSTERONE-INDUCED EXPERIMENTAL PROSTATE ENLARGEMENT IN THE RAT

Authors: PAUBERT-BRAQUET M.; RICHARDSON F.O.; SERVENT-SAEZ N.; GORDON W.C.; MONGE M.C.; BAZAN N.G.; AUTHIE D.; BRAQUET P.

Source: Pharmacological Research, Volume 34, Number 3-4, September 1996 , pp. 171-179(9)

Publisher: Academic Press

Testosterone Metabolism in Primary Cultures of Human Prostate Epithelial Cells and Fibroblasts

Authors: Delos S.; Carsol J.-L.; Ghazarossian E.; Raynaud J.-P.; Martin P.-M.

Source: The Journal of Steroid Biochemistry and Molecular Biology, Volume 55, Number 3, December 1995 , pp. 375-383(9)

Publisher: Elsevier